4,062,500 Common Shares Zynerba Pharmaceuticals, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • July 20th, 2018 • Zynerba Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Introductory. Zynerba Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 4,062,500 shares of its common stock, par value $0.001 per share (the “Shares”). The 4,062,500 Shares to be sold by the Company are called the “Firm Shares.” In addition, the Company has granted to the Underwriters an option to purchase up to an additional 609,375 Shares as provided in Section 2. The additional 609,375 Shares to be sold by the Company pursuant to such option are called the “Optional Shares.” The Firm Shares and, if and to the extent such option is exercised, the Optional Shares are collectively called the “Offered Shares.” Cantor Fitzgerald & Co. (“Cantor”) has agreed to act as representative of the several Underwriters (in such capacity, the “Representative”) in connection with the offering and sale of the Offered Shares. To the extent there are no additional underwriters li
